SEC Filing Reveals GlaxoSmithKline’s 13 Percent Stake in Spero Therapeutics Antibiotics, Antimicrobials, Bacterial Infections, Biomedical Advanced Research and Development Authority (BARDA), Biotech, Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator (CARB-X), Department of Defense, Department of Health and Human Services (HHS), Filings, National Institute of Allergy and Infectious Diseases (NIAID), SEC, Shares, Stakes A filing with the U.S. Securities and Exchange Commission (SEC) indicates that the UK’s GlaxoSmithKline has a 13 percent stake in Spero Therapeutics, with 1,854,006 shares in the Massachusetts biotech company. Read more November 17, 2017/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2017-11-17 12:56:042017-11-17 13:09:42SEC Filing Reveals GlaxoSmithKline's 13 Percent Stake in Spero Therapeutics
